In two trials in uroepithelial carcinoma, the IDO1 inhibitor Epacadostat combined with pablizumab demonstrated a higher objective remission rate (ORR) compared to the pablizumab group, but no benefit was observed from combining Epacadostat in trials in other tumors (34). Here, IDO1 is linked to urothelial carcinoma.